ConceptSet

Anti-Asthmatic Agent, Drug Exposure


Variable Name

rx_antiasthmatic

Refreshed Date

2024-05

Files

1 Download↓
all_antiasthmatic_V3.csv (2.07 MB)
↓

Tags



Level of Review

Data Model

Vocabularies


Broad concept set intended to identify patients with an exposure to an anti-asthmatic agent to identify patient asthma severity.


Variable Status

Funder(s)

Provenance

This concept set was developed for the "Effect of Dupilumab on Onset of Type 1 Disease" study (Incidence of Autoimmune Diseases in Children with Atopy Treated with Dupilumab) to define a cohort of patients with moderate-to-severe atopic disease, including moderate-to-severe asthma and reused without modification in the Researching COVID to Enhance Recovery (RECOVER) Post-Acute Sequelae of SARS-CoV-2 (PASC) Electronic Health Record (EHR) Cohort Study.

Description

The new concept set contains asthma medications which include: combination medications (ICS and LABA), zileuton, theophylline, LTRA, LABA, ICS, SABA and Cromolyn, and asthma injections. The new concept set is a more comprehensive list (including descendants) of combination medications (ICS and LABA), zileuton, theophylline, LTRA, LABA, ICS, SABA and Cromolyn, and asthma injections. RxNorm and RxNorm extension codes and descendants were included. This medication list was partially based on an asthma severity computable phenotype published by Peer et al. (2021, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8328264/).

The full concept set was not reviewed (descendants caused the list to be very large), but Dr. Jonathan Spergel and Dr. Stan Gabryszewski reviewed the concepts used to generate the list. The concept set was generated to identify patients with an indication of atopic disease, including asthma, and to identify asthma severity based on asthma medications.

Medication Term Classes




Clinical Subjects Headings

Development Code

Study Variable Applications

The Researching COVID to Enhance Recovery (RECOVER) Post-Acute Sequelae of SARS-CoV-2 (PASC) Electronic Health Record (EHR) Cohort Study
Study Dates:2021-10 - 2026-05Sponsor Site:PEDSnet Data Coordinating Center
Study to understand, prevent, and treat post-acute sequelae of SARS-CoV-2 (PASC), including Long COVID.
#### [View the RECOVER initiative website here.](https://recovercovid.org/)
Effect of Dupilumab on Onset of Type 1 Disease
Study Dates:2023-06 - 2026-08Sponsor Site:Children's Hospital of Philadelphia
Study to determine whether use of the Type 2 blocker dupilumab in children with atopic dermatitis and asthma is associated with increased frequency of developing Type 1 disease.

Published Research Applications

Data Source

PEDSnet Production Database (2024-04)
Created:2024-04
PEDSnet production database containing de-identified aggregate electronic healthcare information for ten contributing pediatric healthcare institutions. This database corresponds to Version 5.3 of the PEDSnet data model.

#### **Learn about how to access PEDSnet data for research [here](https://pedsnet.org/database/access-to-data/).**
#### **Submit a [collaboration request](https://pedsnet.org/work-with-us/collaboration-request/).**

Related Phenotype

Related Person

Related Concept Set

Related Code

Creative Commons license

a CC-BY Attribution 4.0 License.
Except where otherwised noted, this item's license is described as a CC-BY Attribution 4.0 License.


Version History

Now showing 1 - 3 of 3
VersionDateSummary
3*
 2026-08-27 08:55:32
Modified to be more comprehensive list (including descendants) of combination medications (ICS and LABA), zileuton, theophylline, LTRA, LABA, ICS, SABA and Cromolyn, and asthma injections.
2
 2024-09-24 15:19:37
Expanded codeset for Urban Greenspace study.
1
 2024-06-10 15:03:37
Narrow codeset for RECOVER
* Selected version